Hend Smaoui, Lassaad Chtourou, Dana Jallouli, Samar Ben Jemaa, Iheb Karaa, Mouna Boudabbous, Manel Moalla, Hela Gdoura, Leila Mnif, Ali Amouri, Rim Akrout, Fatma Ayadi, Sofien Baklouti, Nabil Tahri
{"title":"Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density.","authors":"Hend Smaoui, Lassaad Chtourou, Dana Jallouli, Samar Ben Jemaa, Iheb Karaa, Mouna Boudabbous, Manel Moalla, Hela Gdoura, Leila Mnif, Ali Amouri, Rim Akrout, Fatma Ayadi, Sofien Baklouti, Nabil Tahri","doi":"10.2144/fsoa-2023-0198","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass. <b>Methods:</b> This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment. <b>Results:</b> A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent. <b>Conclusion:</b> Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"FSO977"},"PeriodicalIF":2.4000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152587/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2144/fsoa-2023-0198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass. Methods: This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment. Results: A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent. Conclusion: Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.
期刊介绍：
Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
